Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 209-216

  Dan, Yock Young ^a   Ferrante, Shannon A ^b   Elbasha, Elamin H ^b   Hsu, Tun Ying ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Regional Headquaters   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEALTH CARE COST; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MARKOV MODEL; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PUBLIC HOSPITAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SINGAPORE; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROLINE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; RIBAVIRIN; SINGAPORE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84937538473     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2825     Document Type: Article

References (34)

1. WHO. Hepatitis C fact sheet number 164. (Updated July 2013. Accessed 5 December 2013.) Available from http://www.who.int/mediacentre/factsheets/fs164/en/
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2013; 57:1333-1342.
3. Li SC, Lim SG, Yeoh KG, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004; 38:S136-S143.
4. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
6. Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013; 13:190.
7. Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AE, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013; 11:65-78.
8. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36:104-114.
9. Poordad F, Bronowick JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143:608-618.
10. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment related clearance for patients with hepatitis C. BMC Med 2013; 11:6.
11. WHO. CHOosing Interventions that are Cost Effective (WHO-CHOICE (Updated 2013. Accessed 14 January 2013.) Available from http://www.who.int/choice/costs/CER-thresholds/en/index.html
12. 2012 Gross domestic product (GDP). Department of Statistics, Singapore. (Updated February 2013. Accessed 25 February 2013.) Available from http://www.singstat.gov.sg/stats/keyind.html
13. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebeert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156:279-290.
14. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
15. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
16. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997; 92:66-72.
17. Serfaty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-1440.
18. Benvegnú L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48:110-115.
19. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17 year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
20. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
21. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-758.
22. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131:174-181.
23. Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011; 46:92-100.
24. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-830.
25. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.
26. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:1003-1019.
27. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009; 50:89-99.
28. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16:748-759.
29. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652-657.
30. Yearbook of statistics Singapore. 2013: Population. Department of Statistics, Singapore. (Updated 7 August 2013. Accessed 10 August 2013.) Available from http://www.singstat.gov.sg/publications/publications-and-papers/reference/yearbook-2013/excel/topic3.xls
31. Wolfe R, Roys E, Merion R. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:961-972.
32. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
33. Wilson J, Yao G, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11:1-202.
34. Gerkens S, Nechelput M, Annemans L, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007; 14:523-536.